Safety worries hamper emerging therapies.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Decreased expression and function of sodium-glucose co-transporter 2 from a novel C-terminal mutation: a case report
BMC Nephrology Open Access 21 March 2016
-
Recombinant glucagon: a differential biological activity
AMB Express Open Access 12 March 2015
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Related links
Related links
Related links in Nature Research
Dual-action drug shows promise against diabetes 2013-Oct-30
Gastric bypass makes gut burn sugar faster 2013-Jul-25
Gut microbe may fight obesity and diabetes 2013-May-13
Liver hormone offers hope for diabetes treatment 2013-Apr-25
Evidence mounts against diabetes drug 2010-Jun-28
Blog post: US agency reverses stance on controversial diabetes drug
Blog post: FDA advisors vote against new diabetes drug
Related external links
Rights and permissions
About this article
Cite this article
Ledford, H. Diabetes drugs ride a bumpy road. Nature 504, 198 (2013). https://doi.org/10.1038/504198a
Published:
Issue date:
DOI: https://doi.org/10.1038/504198a
This article is cited by
-
Decreased expression and function of sodium-glucose co-transporter 2 from a novel C-terminal mutation: a case report
BMC Nephrology (2016)
-
Recombinant glucagon: a differential biological activity
AMB Express (2015)
-
Cardiovascular Safety of New Drugs for Diabetes: Getting the Balance Right?
Pharmaceutical Medicine (2014)
-
Diabetesprävention durch Phentermin-Topiramat-Kombinationspräparat
Der Diabetologe (2014)
